Pemphigus Vulgaris Treatment Market Expands with Novel Anti-CD20 Antibody Approvals in 2025 | F. Hoffmann-La Roche Ltd, Pfizer Inc, Teva Pharmaceutical Industries

"The Global Pemphigus Vulgaris Treatment Market reached US$473.4 million in 2023 and is expected to reach US$896.1 million by 2031, growing with a CAGR of 8.3% during the forecast period 2024-2031," according to DataM Intelligence.

The Pemphigus Vulgaris treatment market features a strong lineup of pharmaceutical leaders and emerging biotech innovators. Roche, Pfizer, Novartis, Sanofi, AbbVie, and AstraZeneca dominate with their biologic and immunomodulatory portfolios. Teva, GSK, and Zydus Group bolster the market with generic therapies and biosimilars. Meanwhile, Syntimmune is advancing FcRn inhibitor platforms, rounding out a competitive landscape driven by R&D investment and differentiated therapy offerings.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/pemphigus-vulgaris-treatment-market?jd

Pemphigus Vulgaris Treatment Market M&A & Strategic Collaborations

1. Roche-Syntimmune FcRn Inhibitor Licensing Deal
In June 2025, Roche secured global rights to Syntimmune's FcRn-blocking antibody for pemphigus, aiming to fast-track development through a strategic licensing collaboration.

2. Pfizer Acquires Dermatology Biotech Skintera Therapeutics
In May 2025, Pfizer completed its acquisition of Skintera to enhance its dermatology pipeline with novel anti-inflammatory biologics targeting pemphigus.

3. AbbVie-Zydus Biosimilar Partnership for Rituximab in PV
In July 2025, AbbVie formed a partnership with Zydus to develop and commercialize rituximab biosimilars for autoimmune skin disorders, with pemphigus vulgaris as a core indication.

As per our analysis, these developments reflect the industry pivot toward strategic licensing, targeted acquisitions, and biologic innovation, bolstering treatment pipelines and global access for PV patients.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pemphigus-vulgaris-treatment-market?jd

Key Growth Drivers & Emerging Opportunities in the Pemphigus Vulgaris Market

• Shift toward biologics and specialty immunotherapies, such as anti-CD20 and FcRn inhibitors
• Regulatory support for orphan drugs and accelerated approval pathways
• Rising disease awareness and improved diagnostic capabilities among dermatologists
• Emergence of biosimilars, driving affordability and wider access to therapies
• Strategic collaborations between big pharma and biotech, enabling global development and distribution

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pemphigus-vulgaris-treatment-market?jd

Regional Market Drivers for Pemphigus Vulgaris Treatment

North America leads with proactive diagnosis, reimbursement for biologics, and robust clinical trial presence.
Europe benefits from orphan drug incentives, broader insurance coverage, and multi-country healthcare frameworks.
Asia-Pacific is rapidly advancing with expanding dermatologist networks, rising healthcare funding, and regulatory alignment on biologics.
Latin America and the Middle East & and Africa are emerging markets where international partnerships and access programs support market growth.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.